exporting, directly or indirectly dealing in pharmaceutical products, compound or formulation containing Vildagliptin alone or Vildagliptin + Metformin Hydrochloride in combination or Vildagliptin in combination with ... stock of infringing pharmaceutical formulations, compound or combinations comprising Vildagliptin alone and/or Vildagliptin in combination with Metformin Hydrochloride or any other compound or formulation
marketing pharmaceutical products containing the
active pharmaceutical ingredient (API) Vildagliptin (subject matter of
the suit patent), under co-marketing agreement with Plaintiff ... superior and high quality. Plaintiff no. 2 markets in
India Vidagliptin and Vildagliptin + Metformin Hydrochloride in
combination under the brands GALVUS and GALVUSMET
respectively. Similarly
indirectly dealing in Active Pharmaceutical Ingredient (API), pharmaceutical products, or formulations containing Vildagliptin alone or Vildagliptin in combination with any other compound ... manufacture and sale of infringing pharmaceutical products or formulation or combination containing Vildagliptin alone or Vildagliptin in combination in any form and a decree
Single Judge
has noted that the patent relates to a pharmaceutical product Vildagliptin.
It treats Type 2 Diabetes Mellitus. The learned Single Judge has noted ... have three
pending patent applications before the Indian Patent Office relating to
Vildagliptin formulations, Vildagliptin and Metformin hydrochloride
formulations under the brands GALVUS and GALVUSMET
directly or indirectly active pharmaceutical ingredient (API), pharmaceutical products or formulations containing Vildagliptin alone or Vildagliptin + Metformin Hydrochloride in comination or Vildagliptin in combination with ... defendant, in the event of manufacture and sale of any Vildagliptin API or infringing pharmaceutical products or formulation containing Vildagliptin alone or Vildagliptin + Metformin Hydrochloride
indirectly dealing in Active Pharmaceutical Ingredient (API), Pharmaceutical products, or formulation containing Vildagliptin alone or Vildagliptin in combination with any other compound ... stock of infringing pharmaceutical formulations, compound of combinations comprising Vildagliptin alone and/or Vidagliptin in combination with any other compound or formulation available with
exporting, directly or indirectly dealing in pharmaceutical products, compound or formulation containing Vildagliptin alone or Vildagliptin + Metformin Hydrochloride in combination or Vildagliptin in combination with ... stock of infringing pharmaceutical formulations, compound or combinations comprising Vildagliptin alone and/or Vildagliptin in combination with Metformin Hydrochloride or any other compound or formulation
indirectly dealing in active pharmaceutical ingredient (API), pharmaceutical products or formulations containing Vildagliptin alone or Vildagliptin in combination with any other compound ... defendants, in the event of manufacture and sale of any Vildagliptin API or infringing pharmaceutical products or formulation containing Vildagliptin alone or Vildagliptin with
Page 1 of 4
C/AO/189/2015 ORDER
formulation containing Vildagliptin exclusively or with
Metformin Hydrochloride in combination or Vildagliptin in
combination with ... exporting, directly or indirectly,
dealing in pharmaceutical products component or
formulation containing Vildagliptin alone or
Vildagliptin + Metformin Hydrochloride in
combination or Vildagliptin in combination with
product and New Chemical Entity (NCE), assigned International Non-Proprietary Name (INN) Vildagliptin. The petitioner is said to operate in India through its subsidiary which ... markets patented product Vildagliptin in India. The petitioner claims to have spent substantial financial resources on pharmaceutical research and development in order to invent
